Association of TLR4-T399I Polymorphism with Chronic Obstructive Pulmonary Disease in Smokers by Speletas, Matthaios et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2009, Article ID 260286, 6 pages
doi:10.1155/2009/260286
Research Article
Association of TLR4-T399I Polymorphism with
ChronicObstructive Pulmonary Disease in Smokers
MatthaiosSpeletas,1 VassilikiMerentiti,1 Konstantinos Kostikas,2 Kyriaki Liadaki,1
Markos Minas,2 Konstantinos Gourgoulianis,2 and AnastasiosE. Germenis1
1Department of Immunology and Histocompatibility, University of Thessaly Medical School, 41110 Larissa, Greece
2Respiratory Medicine Department, University of Thessaly Medical School, 41110 Larissa, Greece
Correspondence should be addressed to Matthaios Speletas, maspel@med.uth.gr
Received 5 August 2009; Revised 9 December 2009; Accepted 30 December 2009
Recommended by Nima Rezaei
Tobacco smoking has been considered the most important risk factor for chronic obstructive pulmonary disease (COPD)
development. However, not all smokers develop COPD and other environmental and genetic susceptibility factors underlie disease
pathogenesis. Recent studies have indicated that the impairment of TLR signaling might play a crucial role in the development
of emphysema. For this purpose we investigated the prevalence and any possible associations of common TLR polymorphisms
(TLR2-R753Q, TLR4-D299G, and TLR4-T399I) in a group of 240 heavy smokers (>20 pack years), without overt atherosclerosis
disease, of whom 136 had developed COPD and 104 had not. The presence of TLR4-T399I polymorphism was associated
with a 2.4-fold increased risk for COPD development (P = .044), but not with disease stage or frequency of exacerbations.
Considering that infections contribute to COPD and emphysema pathogenesis, our ﬁndings possibly indicate that dysfunctional
polymorphisms of innate immune genes can aﬀect the development of COPD in smokers. Although this ﬁnding warrants further
investigation, it highlights the importance of impaired innate immunity towards COPD development.
Copyright © 2009 Matthaios Speletas et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Emerging evidence suggests that immune cells accumulate
in bronchial biopsy specimens in patients with chronic
obstructive pulmonary disease (COPD) [1, 2], questioning
inthiswaywhetherthelungdestructioninCOPDisimmune
cell driven. Tobacco smoking has been identiﬁed as the
most important risk factor of the disease [3, 4], interfering
with the innate host defense system by damaging cells
throughtheattackofoxidants,increasingmucusproduction,
reducing mucociliary clearance, and disrupting the epithelial
barrier [1]. Considering that less than 20% of smokers
develop COPD [3–5], it has been suggested that additional
susceptibilityfactorsmightbeimplicatedinlungobstruction
and emphysema development [2, 6, 7].
It is well accepted nowadays that factors favoring infec-
tions contribute to COPD development, since air pollution,
latent adenoviral infections, and childhood respiratory
infections have been implicated in disease pathogenesis,
in a proportion of patients [3, 4, 8]. In this context,
recent studies have demonstrated that impaired signaling of
innate immunity receptors may contribute to COPD and
emphysema pathogenesis [9–11]. Amongst these receptors,
Toll-like receptor (TLR) 4 seems to play a pivotal role in lung
homeostasis by contributing to the defense of endothelial
cells against oxidants [9, 10]. Moreover, TLR4-knockout
mice (Tlr4−/− mice) spontaneously develop emphysema,
associated with an oxidant/antioxidant imbalance, due to
increasedNox3geneexpressionandelastindegradation[11].
The impairment of TLR signaling in vivo becomes evident
through the presence of single nucleotide polymorphisms
(SNPs) that have been associated with receptor hypo-
responsiveness and susceptibility to bacterial, fungal, and
viral infections (reviewed by Schroder and Schumann) [12].
Amongst TLRs, TLR-4 recognizes lipopolysaccharides
of Gram (−) bacteria, while TLR-2 recognizes endogenous
inﬂammatory mediators in addition to microbial products
like lipotheicoic acid of Gram (+) bacteria [12], namely,
the pathogens that play a crucial role, at least, in COPD
phenotype (frequency and severity of exacerbation attacks)2 Clinical and Developmental Immunology
[13]. Thus, based on the abovementioned data, the present
study was designed to analyze the prevalence of common
TLR SNPs, namely, TLR2-R753Q, TLR4-D299G, and TLR4-
T399I, in a cohort of smokers with and without COPD, in
order to demonstrate their possible contribution to disease
pathogenesis and phenotype.
2.MaterialsandMethods
2.1. Study Population. One hundred and thirty-four (134)
Greek patients with COPD (male/female: 133/1, mean age:
69.4 years, range: 39–88) and 106 Greek smokers without the
disease (male/female: 102/4, mean age: 63 years, range: 40–
84), who were randomly selected between October 2005 and
October 2008, were enrolled in the study. Individuals with
a history of severe cardiovascular comorbidities (including
coronary artery disease or stroke) were excluded from the
study. Additionally, individuals with coexisting asthma or
atopy, autoimmune diseases, and cancer were not enrolled
in the study.
All participants had a smoking history of more than 20
pack years (pys) and were current smokers or ex-smokers,
the latter being deﬁned as having quit smoking for more
than one year. All participants, including normal controls,
were submitted to physical examination and spirometry and
ﬁlled in a detailed questionnaire, including the presence of
respiratory symptoms (e.g., cough, sputum, and dyspnoea).
Dyspnoea severity was estimated according to the Medical
Research Council (MRC) scale.
COPD diagnosis was based on spirometric data showing
airway obstruction (forced expiratory volume in one second
[FEV1]/forced vital capacity [FVC] < 70%) in individuals
with a smoking habit >20pys, according to the Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD) 2007
guidelines [13]. Classiﬁcation of COPD severity was based
on postbronchodilator FEV1, according to GOLD guidelines
(Stage I—mild COPD FEV1 ≥ 80.0% predicted; Stage II—
moderate COPD 50.0% ≤ FEV1 < 80.0% predicted; Stage
III—severe COPD 30.0% ≤ FEV1 < 50.0%; Stage IV—very
severe COPD 30.0% ≤ FEV1, or FEV1 < 50.0% predicted
with respiratory failure) [13]. Spirometry was carried out
with a dry spirometer (Koko Legend, Ferraris Louisville, CO,
USA) according to the American Thoracic Society guidelines
[14]. Patients exhibiting three or more COPD exacerbations,
or two or more exacerbations including one hospitalization
due to COPD in the previous year, were considered frequent
exacerbators. The evaluation of exacerbation status was
based on patient records and was available in 123 out of
134 COPD patients. Clinical and demographic data of the
enrolled individuals are presented in Table 1.
All subjects provided written informed consent. The
study was conducted in accordance with the principles
of Helsinki declaration and was approved by the Institu-
tional Review Board of the University Hospital of Larissa,
Greece.
2.2. Molecular Techniques. Genomic DNA was extracted
from peripheral blood using the QIAamp DNA Blood Mini
Kit (Qiagen), according to manufacturer’s instructions.
The detection of the TLR4-D299G and TLR4-T399I poly-
morphisms was performed by allele-speciﬁc PCR followed
by restriction fragment length polymorphism (PCR-RFLP)
analysis, as described previously [15, 16]. In brief, the
forward primers, in both reactions, were modiﬁed at the 5 
end, creating restriction enzyme recognition sites (NcoI for
the TLR4-D299G polymorphism and HinfI for the TLR4-
T399I), so that if a polymorphism is present, then PCR-
RFLP analysis will create digestion fragments, visible on
agarose gels [15, 16]. The detection of the TLR2-R753Q
polymorphism was also performed by PCR-RFLP, since the
presence of polymorphism results in the alteration of DNA
sequencing, allowing digestion by SfcI [17]. Primers used
for the PCR ampliﬁcation of TLR2 gene were previously
described by Ogus et al. [18]. All PCR and digestion
procedures were carried out in the PCR-engine apparatus
PTC-200, MJ-Research (Watertown, Massachusetts), while
the PCR and digestion products were analyzed in 2% TBE
agarose gels.
For the conﬁrmation of PCR-RFLP results, randomly
chosen PCR products, positive and negative for the TLR
polymorphisms, were puriﬁed by Qiagen PCR Puriﬁcation
System (Qiagen, UK) and sequenced using an ABI Prism
310 Genetic Analyzer (Applied Biosystems, Foster City, CA)
and a Big Dye Terminator DNA sequencing kit (Applied
Biosystems).
2.3.StatisticalAnalysis. Chi-square(χ2)testalongwithYates’
correction was used to compare the allele and genotype fre-
quencies between disease and control groups. Fisher’s exact
test was used when appropriate. The association between
COPD and TLR polymorphisms, and the other categorical
clinicolaboratory variables of interest, was tested using a
univariate logistic regression model. Continuous variables
were compared using the nonparametric Mann-Whitney U-
test. An association was expressed as odds ratio (OR) with
the corresponding 95% conﬁdence interval (CI). A variable
was considered signiﬁcant when P<. 05. The above analyses
wereperformedusingSPSS(version10.0,Chicago,IL,USA).
Attheend,thedeviationsfromHardy-Weinbergequilibrium
were evaluated using the freely available software Arlequin
3.11 (http://cmpg.unibe.ch/software/arlequin3/).
3. Results
3.1. TLR Polymorphisms Analysis in COPD Patients and
Normal Smokers. Examples of the detection of TLR poly-
morphisms by PCR-RFLP are presented in Figure 1.D i r e c t
sequencing of 32 randomly chosen samples (5 heterozygotes
for both TLR4 polymorphisms, 2 heterozygotes for the
TLR2-R753Q, and 25 wild-type) conﬁrmed the results of
PCR-RFLP analysis. No one individual was homozygous for
any TLR polymorphism. The allele and genotype frequencies
of the TLR4-T399I SNP were signiﬁcantly increased in
patients with COPD when compared to normal smokers
(P = .046 and P = .039, resp.). Moreover, an increased
frequency of the TLR4-D299G allele in COPD was alsoClinical and Developmental Immunology 3
Table 1: Clinical and demographic data of study population.
Variable
COPD Healthy
patients smokers
(n = 134) (n = 106)
Sex
Male (n, %) 133 (99.25) 102 (96.23)
Female (n, %) 1 (0.75) 4 (3.77)
Age (years ± STDEV) 69.4 ± 8.9 63 ± 9.6
BMI (Kg/m2) (mean ± STDEV) 27.9 ± 5.8 27.7 ± 5.8
<30Kg/m2 (n, %) 96 (71.6) 74 (69.8)
≥30Kg/m2 (n, %) 38 (28.3) 32 (30.1)
Smoking status
Current Smokers (n, %) 53 (39.5) 74 (69.8)
Ex Smokers (n, %) 81 (60.4) 32 (30.1)
Pys (mean ± STDEV) 70.9 ± 37.8 54.8 ± 23.3
COPD stage
Mild (FEV1 ≥ 80%) (n,% ) 6( 4 . 4 )
Moderate (FEV1: 50%–79%) (n, %) 74 (55.2)
Severe (FEV1: 30%–49%) (n, %) 40 (29.8)
Very severe (FEV1 < 30%) (n, %) 14 (10.4)
Frequency of exacerbations
Frequent exacerbators (n, %) 34 (27.6)
Nonfrequent exacerbators (n, %) 89 (72.3)
Abbreviations: COPD, chronic obstructive pulmonary disease; BMI, body
mass index; Pys, pack years.
observed but failed to reach statistical signiﬁcance (P =
.061). Considering the prevalence of the TLR2-R753Q, no
signiﬁcant diﬀerence between COPD patients and healthy
smokers was observed (P = .117). Logistic regression
analysis revealed that individuals carrying the TLR4-T399I
polymorphism displayed a 2.4-fold increased risk to develop
COPD (95% CI: 1.02–5.64, P = .044). Other variables
associated with COPD development were age (P<. 001)
and pys (P<. 001). Considering the impact of the
other polymorphisms, no signiﬁcant diﬀerence was observed
(Table 2).
TLR4-T399I polymorphism was strongly associated with
the value of FEV1/FVC ratio (P = .032) but not with disease
stage and the frequency of exacerbations (P = .130 and P =
.562, resp.). On the other hand, no signiﬁcant correlation
of the TLR2-R753Q and TLR4-D299G polymorphisms was
observed with the evaluated parameters.
Moreover, positive strong correlations of COPD stage
with pys (P<. 001) and the frequency of exacerbations (P<
.001) were found. Finally, the exacerbations of COPD were
observed more frequently among heavy smokers (P = .015).
3 . 2 .T h eH a r d y - W e i n b e r gP r i n c i p l ea m o n gT L RS N P s .The
analysis suggests that both of the TLR4 gene polymorphisms
obey Hardy-Weinberg principle in the group of COPD
patients (P = .616 and P = .585, for the D299G and T399I
SNPs,resp.)andnormalsmokers(P = .064andP = .922,for
the D299G and T399I SNPs, resp.). Moreover, TLR2-R753Q
SNP shares the same deviant behavior in both populations
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Figure 1: (a) Representative digestions showing the TLR2-R753Q
(A), TLR4-D299G (B), and TLR4-T399I (C) polymorphisms.
M: 200bp ladder molecular weight marker. Lanes 1–8: Patients
with COPD; lane 9: negative PCR control. Samples without any
polymorphism (1,3,4,8) display undigested PCR products, 430bp
for the TLR2-R753Q, 249bp for the TLR4-D299G, and 407bp for
the TLR4-T399I. Samples 5 and 7 are heterozygotes for the TLR2-
R753Qpolymorphism,whereastheTLR2-753QallelecontainsaSfc
I restriction site resulting in 307bp and 123bp fragments. Samples
2 and 6 are double heterozygotes for both TLR4 polymorphisms.
In particular, the TLR4-299G allele contains an NcoI restriction
site resulting in 218bp and 31bp fragments, while the TLR4-
399I allele contains a HinfI restriction site resulting in 375bp
and 28bp fragments. The digestion products were analyzed on
2 %o fT B Ea g a r o s eg e l sa n dt h e2 8 b pa n d3 1 b pf r a g m e n t sa r e
not visible on agarose gels. (b) Representative sequencing analysis
shows the presence of TLR2-R753Q, TLR4-D299G, and TLR4-
T399I polymorphisms.
(P = .976 and P = .940 for COPD patients and normal
smokers, resp.).
To this end, we conﬁrmed that the G allele of TLR4-
D299G SNP has a high level of linkage disequilibrium with
the allele C of TLR4-T399I SNP (P<. 001), for both COPD
patients and normal smokers, as reported previously [19].
4. Discussion
To the best of our knowledge, this is the ﬁrst report ex-
amining a possible association of several common TLR4 Clinical and Developmental Immunology
Table 2: Distribution of the TLR SNPs in smokers with and without COPD.
Variable COPD patients (n = 134) Controls (n = 106) P OR (95% CI)
TLR2-R753Q genotype G/G (wt) 129 103 .311
(2258G/A) G/A (het) 5 3
A/A (hom) 0 0
alleles (n, %) G 263 (98.1) 487 (96.7) .317 0.54 (0.16–1.77)
A 5 (1.9) 3 (3.3)
TLR4-D299G genotype A/A (wt) 113 97 .095
(896A/G) A/G (het) 21 9
G/G (hom) 0 0
alleles (n, %) A 247 (92.2) 203 (95.8) .100 2.0 (0.87–4.57)
G 21 (7.8) 9 (4.2)
TLR4-T399I genotype C/C (wt) 112 98 .039
(1196C/T) C/T (het) 22 8
T/T (hom) 0 0
alleles (n, %) C 246 (95.7) 204 (96.3) .044 2.4 (1.02–5.64)
A 22 (8.2) 8 (3.7)
Haplotypes (n,%)
TLR2-753R/TLR4-299D-399T - TLR2-753R/TLR4-299D-399T 110 (82.1) 90 (84.9) .081
TLR2-753R/TLR4-299D-399T - TLR2-753R/TLR4-299G-399I 20 (14.9) 8 (7.5)
TLR2-753R/TLR4-299D-399T - TLR2-753R/TLR4-299G-399T 0 (0) 1 (0.9)
TLR2-753R/TLR4-299D-399T - TLR2-753R/TLR4-299D-399T 1 (0.7) 0 (0)
TLR2-753R/TLR4-299D-399T - TLR2-753Q/TLR4-299D-399I 2 (1.5) 7 (6.6)
TLR2-753R/TLR4-299D-399T - TLR2-753Q/TLR4-299G-399I 1 (0.7) 0 (0)
Abbreviations: COPD, chronic obstructive pulmonary disease; CI, conﬁdence intervals; wt, wild-type; het, heterozygous; hom, homozygous.
polymorphisms with COPD development and severity in
smokers. Clear evidence is presented for a novel association
between TLR4-T399I polymorphism and susceptibility to
COPD in Greek smokers, in view of the higher frequency of
TLR4-399I allele in smokers with COPD compared to that of
healthy ones.
We should underscore that the sample size in our
study was relatively small, and thus, the power of detecting
signiﬁcant results was limited (almost 20%). However,
candidate-gene association studies have the tendency to lack
the power to detect a statistically signiﬁcant association. For
example, in order to achieve a power >80% to identify a
modest genetic eﬀe c t( o d d sr a t i o1 . 2 )o fap o l y m o r p h i s m
present in 10% of individuals, a sample size of 10,000
subjects or more would be needed [20]. Therefore, the
sample sizes required to predict association have to be far
beyond what is currently available and no single institution
orentityalonewillbeabletoprovideareasonablenumberof
patients. However, a future meta-analysis of multiple studies
clearly has a role in oﬀering an analysis with the potential
f o rh i g h e rp o w e r[ 21]. Future collaborative studies may
allow the pooling of data, providing more power to detect
signiﬁcant associations. Furthermore, consortia performing
gene-candidate or genome wide associations studies will be
able to replicate the validity of the present ﬁndings [21, 22].
The two TLR4 SNPs analyzed in this study (D229G and
T399I) are located in the extracellular domain of the human
TLR4. These result in impaired TLR4 signaling, since they
have been associated with receptor hyporesponsiveness in
alveolar macrophages and epithelial cells, and peripheral
blood mononuclear cells [19]. It has been estimated that the
tracheobronchial tree of stable COPD patients is colonized
with bacteria and viruses in approximately 30% of cases,
many of which are recognized by TLR4, such as H. inﬂuenzae
and M. catarrhalis [23]. Thus, any TLR4 dysfunction, such
as the presence of T399I polymorphism, might reduce the
clearance of the abovementioned pathogens, contributing to
COPD pathophysiology. This is in accordance with previous
studies where an aberrant innate immune response, being
demonstratedbyalterationsoflungcytokines,oxidantstress,
and TLR4 signaling, has been associated with experimental
emphysema [7, 9–11].
Till now, only two groups have been examined pre-
viously, the possible association of the TLR4-D299G SNP
with COPD development, with conﬂicting ﬁndings [24, 25].
Rohde et al., having included a proportion of nonsmokers in
the analyzed COPD group, reported a decreased frequency
of TLR4-D299G in COPD patients compared to normal
controls [24]. However, the interpretation of these results
warrants caution, since no smoking habit determination
was performed for the control group. For the latter, we
consider it to be a very important issue in the design of
disease association studies. On the other hand, Sabroe et
al. screened a population of 289 smokers and observed
no association between TLR4-D299G polymorphism and
lung function [25]. However, they avoided describing their
patients as COPD patients, whilst no details about clinical
symptoms deﬁning COPD are given. On the other hand, ourClinical and Developmental Immunology 5
ﬁndings suggest that there is no association of the TLR2-
R753Q polymorphism with either the onset or the course
of COPD. This is in accordance with the recent work by
Pabst et al., where a similar ﬁnding was observed analyzing
COPD patients and controls, including a signiﬁcant number
of nonsmokers [26].
Considering the presence of linkage disequilibrium for
the two TLR4 polymorphisms, we would expect similar
results for the TLR4-D299G SNP to those observed for the
TLR4-T399I. However in our study, although the presence
of TLR4-D299G polymorphism was associated with a 2-fold
increased risk for COPD development, this diﬀerence did
not reach statistical signiﬁcance (Table 2). It is worth of note
that initial in vitro studies indicated that the TLR4-D299G
genotype might have a greater functional impact compared
with that of the TLR4-T399I genotype [19]. However, this
might not be the case in vivo, since recent gene association
studies have shown that the abovementioned SNPs could
aﬀect disease development in a diﬀerent way. For example,
Kiechl et al. observed that the TLR4-D299G SNP has a more
profound protective eﬀect to atherosclerosis risk than TLR4-
T399I [27], while T¨ or¨ ok et al. described that only TLR4-
T399I SNP aﬀects the susceptibility to ulcerative colitis [28].
It is obvious that further studies using appropriate animal
models could verify the role of TLR4-T399I polymorphism.
To this end, the present study has two major distinguish-
ing factors compared to previous ones. First was the analysis
of the TLR4-T399I polymorphism and second was the fact
that no individuals with overt coronary artery disease or
stroke were enrolled, considering the possible contribution
of TLR4 SNPs in atherosclerosis development [27].
5. Conclusions
A novel association between a functional polymorphism in
TLR4(T399I)andCOPDisreported.Consideringthatinfec-
tionscontributetoCOPDandemphysemapathogenesis,our
ﬁndings possibly indicate that dysfunctional polymorphisms
of innate immune genes can aﬀect the development of
COPD in smokers. Although this ﬁnding warrants further
investigation,ithighlightstheimportanceofimpairedinnate
immunity towards COPD development.
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